Titan Pharmaceuticals Announces Positive Results From Phase III Clinical Trial Of Probuphine For The Treatment Of Opioid Addiction

Titan Pharmaceuticals, Inc. (AMEX:TTP) announced positive, statistically significant results from its randomized, double-blind, placebo controlled, multi-center Phase III clinical trial of Probuphine®. Probuphine is Titan’s novel, subcutaneous implant formulation designed using its ProNeura technology to deliver six months of buprenorphine. Buprenorphine is currently marketed as a sublingual formulation for the treatment of opioid addiction.

More: continued here

Filed under: Alcohol / Addiction / Illegal Drugs on July 31st, 2008